Akari Therapeutics (NASDAQ:AKTX) Stock Price Expected to Rise, HC Wainwright Analyst Says

Akari Therapeutics (NASDAQ:AKTX) had its price target hoisted by analysts at HC Wainwright to $27.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Akari Therapeutics in a report on Wednesday, January 21st. LADENBURG THALM/SH SH assumed coverage on Akari Therapeutics in a research note on Monday, January 5th. They issued a “buy” rating and a $40.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $89.00.

Akari Therapeutics Price Performance

Akari Therapeutics stock opened at $4.47 on Wednesday. The firm has a fifty day simple moving average of $8.67 and a two-hundred day simple moving average of $17.75. Akari Therapeutics has a twelve month low of $4.16 and a twelve month high of $63.20.

Akari Therapeutics (NASDAQ:AKTX) last posted its quarterly earnings results on Monday, March 30th. The biopharmaceutical company reported ($2.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($2.65).

Institutional Trading of Akari Therapeutics

A hedge fund recently bought a new stake in Akari Therapeutics stock. Armistice Capital LLC purchased a new stake in Akari Therapeutics PLC (NASDAQ:AKTX) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned approximately 5.95% of Akari Therapeutics as of its most recent SEC filing. 5.06% of the stock is currently owned by institutional investors and hedge funds.

About Akari Therapeutics

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.